KR101820944B1 - Companion animal ophthalmology disease management assistance nutrient and the manufacture Method - Google Patents

Abstract

The present invention relates to a companion animal ophthalmic disease management supplement nutrient and a method for producing the same. Wherein the auxiliary nutrient comprises 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of giazanthin, 1.5 to 2.5 parts by weight of astaxanthin, 4 to 6 parts by weight of DHA, 4 to 6 parts by weight of EPA, 2 to 4 parts by weight of inulin, 1.5 to 2.5 parts by weight of zinc, 1.5 to 2.5 parts by weight of magnesium oxide, 6 to 10 parts by weight of niacin, 6 to 10 parts by weight of pyridoxine, 12 to 18 parts by weight of vitamin E, 12 to 18 parts by weight of vitamin C, And the like.
The adjuvant of the present invention has an effect that can contribute to the treatment of ophthalmic diseases of companion animals.

Description

≪ Desc / Clms Page number 1 > Companion animal ophthalmology disease management assistance nutrient and the manufacture method &

More particularly, the present invention relates to a nutrient and a method for producing a nutrient and a nutrient encapsulated by mixing raw materials such as vitamins and excipients to be ingested by companion animals.

As the population ages and the number of single households increases, people are increasingly self-centered and desperate. As a result, the number of people who recognize pets as family members or companions is increasing, and the pet animal market is also steadily growing. It is expected to expand rapidly to 2 trillion won in 2014 and 6 trillion won in 2020.

As the interest of these companion diseases is getting bigger and bigger day by day, the production and development of medicines for solving these problems are increasing day by day.

However, the development of information and medicines for ophthalmologic diseases, which is a kind of fatal disease that interferes with the maintenance of life span of not only humans but also companion animals, is less developed and researches on them are still poor, There is a problem in that it is difficult to treat and difficult to heal, such as a disease, and it is costly, so that the user must actually put his hand.

Korean Patent Publication No. 2015-0111724 Korean Patent Publication No. 2015-0115980

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made in view of the above problems, and it is an object of the present invention to provide an ophthalmic disease-supporting nutritional supplement having excellent therapeutic effect on ophthalmic diseases of companion animals using raw materials such as lutein and excipient, will be.

In order to achieve the above object, the present invention provides a method for treating ophthalmic disease-associated animal diseases, comprising 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of giazanthin, 1.5 to 2.5 parts by weight of astaxanthin, 4-6 parts by weight of DHA, 2 to 4 parts by weight of inulin, 1.5 to 2.5 parts by weight of zinc oxide, 1.5 to 2.5 parts by weight of magnesium oxide, 6 to 10 parts by weight of niacin, 6 to 10 parts by weight of pyridoxine, 12 to 18 parts by weight of vitamin E, 12 to 18 parts by weight of vitamin C, and 10 to 20 parts by weight of an excipient.

In addition, a mixture of 17.5 to 26.5 parts by weight of an eye nutrient material, 8 to 12 parts by weight of an omega 3 fatty acid, 2 to 4 parts by weight of an inulin, 3 to 5 parts by weight of an oxide, 36 to 56 parts by weight of a vitamin and 10 to 20 parts by weight of an excipient Wherein the mixture obtained by pulverizing the mixture and the powdered mixture is stirred at a predetermined temperature for a certain period of time, and the mixture after the boiling is dried at a predetermined temperature for a certain period of time And a filling step of filling the mixture passed through the drying step with a capsule.

The eye nutritional material is characterized by comprising 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of gyazanthin and 1.5 to 2.5 parts by weight of astaxanthin.

In addition, the oxide is composed of 1.5 to 2.5 parts by weight of zinc oxide and 1.5 to 2.5 parts by weight of magnesium oxide.

Also, the omega-3 fatty acid is composed of 4-6 parts by weight of DHA and 4-6 parts by weight of EPA.

The vitamin is 6 to 10 parts by weight of niacin, 6 to 10 parts by weight of pyridoxine, 12 to 18 parts by weight of vitamin E and 12 to 18 parts by weight of vitamin C.

Further, the lutein may be prepared by mixing 26 to 36 parts by weight of marigold powder, 40 to 50 parts by weight of ethylacetate and 14 to 22 parts by weight of ethanol at a temperature of 10 ° C to 25 ° C in a total amount of 100 parts by weight to prepare a mixed solution, And 10 to 13 parts by weight based on 100 parts by weight of the mixed liquid of step a), separating the marigold extract and the supernatant, and discarding the supernatant separated in the step, and then washing the marigold extract with distilled water to remove anthocyanin and potassium hydroxide. Washing the marigold extract with ethanol and hexane to remove organic impurities to produce lutein, mixing a 1: 1 mixture of dichloromethane and nucleic acid and the lutein, cooling the mixture at a temperature of 20 ° C to 10 ° C for 2 to 3 hours, And then drying for 2 to 3 days under a vacuum of 45 ° C to 55 ° C to produce pure lutein.

Accordingly, the present invention provides a nutrient that can solve such problems in the animal medicine-related pharmaceutical industry, in which there is almost no preventive or therapeutic means such as a certain nutrient for the ophthalmologic diseases of existing companion animals, Which can significantly contribute to the treatment of ophthalmic diseases.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart of a method for manufacturing a companion animal ocular disease supplementary nutrient according to the present invention. FIG.

Hereinafter, the ophthalmic disease adjuvant for companion animals according to the present invention will be described in detail with reference to the drawings.

The ophthalmic pharmaceutical adjuvant of the present invention is characterized in that it is composed of an eye nutritional material, omega 3 fatty acid, inulin, an oxide, a vitamin, and an excipient.

The eye nutrient material consists of lutein, giazantin and astaxanthin.

The omega-3 fatty acids are composed of DHA and EPA.

The oxide is composed of zinc oxide and magnesium oxide.

Vitamins are composed of a mixture of vitamin E, vitamin C, niacin and pyridoxine.

 The weight ratio of each of the materials is 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of gyazanthin, 1.5 to 2.5 parts by weight of astaxanthin, 4 to 6 parts by weight of DHA, 4 to 6 parts by weight of EPA, 4 to 12 parts by weight of vitamin E, 12 to 18 parts by weight of vitamin C, 12 to 18 parts by weight of vitamin C, 1 to 4 parts by weight of zinc oxide, 1.5 to 2.5 parts by weight of zinc oxide, 1.5 to 2.5 parts by weight of magnesium oxide, 6 to 10 parts by weight of niacin, , And 10 to 20 parts by weight of an excipient.

 It is to be understood that the numerical value of the weight portion is a result of many experiments and data.

Hereinafter, the efficacy and effects of each ingredient constituting the supplementary nutrition of the present invention will be described.

First, lutein, gyazanthin, astaxanthin, eye nutritional ingredients are explained.

Lutein is the hormone of the yellow pigment in the luteal cells of the ovary. There are many in the chloroplast of plants. The lutein decreases the density of macular pigment due to aging but maintains the density of the macular pigment, thereby contributing to the health of the eye. The production process of lutein to be described below will be described again in detail.

Zeaxanthin is also a raw material for eye nutrition, which helps to strengthen the eye.

Astaxanthin is a lipid-soluble natural carotenoid with strong antioxidant power, so called Super Vitamin E. If you have a high antioxidant ability that goes beyond β-carotene or vitamin E, it has excellent ability to remove excess oxygen generated in the body, and the ability to remove 'singlet oxygen', which is particularly toxic in active oxygen, More than twice that of β-carotene.

In addition, DHA and EPA, which form omega-3 fatty acids, are described.

DHA and EPA are called omega-3s. When they are distributed in the nerve cell membrane and the retina, they deliver electrical stimulation at the cell membrane to the next cell at a high rate.

In addition, it helps to protect the cells and smooth metabolism, and is known to have a great effect on improving liver function, prevention of adult diseases, eye health, and prevention of osteoporosis.

Inulin is contained in many plants belonging to the Asteraceae family (also called Asteraceae, also called Compositae), especially in the roots and stems of plants such as Dalaria and obturator (Jerusalem artichoke or pig potato). Inulin produces a white and transparent powder that gives the sweetness of sucrose. Inulin molecules are small inactive fructose. It exits without being absorbed through the digestive system, and does not affect cellular activity. Because inulin is not absorbed in the body, it is used to sweeten the food that diabetics eat.

Hereinafter, zinc oxide and magnesium oxide constituting the oxide material will be described.

Zinc Oxide is a compound of oxygen and zinc. It is a light white powder and is also called zincation and zinc bag. It is present from natural to inflorescence and obtained by burning, heating and so on. It is used as medicines, pigment, cosmetic raw materials.

Magnesium oxide (MgO) is a hygroscopic solid mineral that occurs naturally and has a white light, and is a source of magnesium. The magnesium oxide can be used for cement, production site, medicine, and the like.

Hereinafter, niacin pyridoxine, vitamin E, and vitamin C, which are vitamin materials, will be described.

Niacin (vitamin B3) is a nutrient required for total metabolism, participates in the production of neurotransmitters and in maintaining moisture in the skin, and is involved in expanding blood vessels and lowering blood cholesterol levels .

Pyridoxine (pyridoxine) is a water-soluble vitamin that is synthesized by intestinal bacteria in humans, so it is not easily deficient. However, it is not easily absorbed by ingestion due to dietary imbalance, cerebral hemorrhage, etc., Seborrheic dermatitis occurs around eyes, nose, and mouth.

Vitamin E functions to protect cells from free radicals.

Vitamin C enhances the uptake of vitamin E and acts as an anti-oxidant outside the cell.

HPMC (Hydroxypropyl Methylcellulose) is a drug that is used to make medicines easier to eat or to have any color and shape when the amount of the medicine is low in the preparation process of tablets or pills. It is mainly used lactose and starch.

Hereinafter, the manufacturing method of the present invention will be described with reference to FIG. FIG. 1 is a flow chart of a method for manufacturing a companion animal ophthalmic disease supplementary nutrient according to the present invention.

First, the compounding ratio is calculated, and the raw material is weighed using an electronic scale or the like. As described above, 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of ziatin, 1.5 to 2.5 parts by weight of astaxanthin, 4 to 6 parts by weight of DHA, 4 to 6 parts by weight of EPA, zinc oxide of 1.5 to 2.5 12 to 18 parts by weight of vitamin E, 12 to 18 parts by weight of vitamin C, 10 to 20 parts by weight of an excipient 10, 2 to 4 parts by weight of magnesium oxide, 2 to 4 parts by weight of inulin, 6 to 10 parts by weight of niacin, 6 to 10 parts by weight of pyridoxine, To 20 parts by weight. (Mixture preparation step)

The mixture preparation step blends each material to the above-described weight parts by using a blender (not shown). Stirring is carried out at room temperature for about 30 minutes to make uniform components in all parts.

It should be noted that 0.05 to 0.15 parts by weight of the mineral may be further added to the mixture. It is intended to reveal that the range of the weight portion is also the result of many experiments and data. Minerals are about 100 kinds of metal and nonmetal elements and exist in organic matter such as proteins, hemoglobin, enzymes, etc. There are about 20 kinds of inorganic salts in food.

These minerals are only 2 ~ 5% in the body, but they are essential nutrients for the maintenance of life. They are classified into large amounts and small amounts depending on the contents of the body. Among them, calcium and phosphorus account for more than 70% of minerals.

The minerals form a skeleton such as bone tissue or soft tissue in the body, maintain the acid base equilibrium, activate the enzyme, and contribute to osmotic pressure maintenance as a constituent of the body fluid.

Hereinafter, a process for producing lutein, which is a main material in the present invention, will be described.

The lutein is a plant nutrient (carotenoid) found in vegetables, and is a major component of the cornea and the pupil of the eye. It is effective in the treatment of diseases related to eyesight, and is being seen as a nutrient to help tired eye health.

26 to 36 parts by weight of marigold powder, 40 to 50 parts by weight of ethyl acetate and 14 to 22 parts by weight of ethanol are mixed at a temperature of 10 ° C to 25 ° C to prepare a mixed solution. (First step)

Here, the limitation of the temperature and the weight is the result of many experiments and data for extracting lutein using marigold powder so far.

Hereinafter, a method of manufacturing the marigold powder as the material of the first step will be described.

The petals of marigold were hydrolyzed with low molecular weight acetic acid or hydrochloric acid and decomposed into cellulose for about 30 minutes. The hydrolyzed marigold petals are washed with water, dried or sun-dried, and finely pulverized by a pulverizer to produce powder. The particle size is preferably 0.5 mm to 1 mm. This is because the characteristic of the marigold powder is most apparent in the particle size.

Furthermore, a mixing ratio of ethyl acetate to ethanol of 2.3: 1 is preferable. It is also possible to use methanol or isopropyl alcohol instead of ethanol. With equalization, the pH rises to about 11-14, with a pH of about 12. The reaction is completed within 2 hours.

Next, when the reaction is completed, 10 to 13 parts by weight of sodium chloride aqueous solution based on 100 parts by weight of the mixed solution of the first step is added to separate the marigold extract and the supernatant. (Step 2) It is to be noted that the weight part of 10 to 13 parts by weight is also a result of many experiments and data.

After discarding the supernatant separated by the above procedure, the remaining marigold extract is washed with distilled water to remove anthocyanin and potassium hydroxide. (Third step)

In the third step, the filtrate is almost colorless and washed with distilled water until the pH becomes almost neutral. By performing this process, anthocyanin and potassium hydroxide are removed from the marigold extract.

The marigold extract is washed with ethanol and hexane to remove organic impurities to produce lutein. (Step 4)

In the fourth step, the marigold extract which has undergone the third step is cooled to 0 to 5 ° C in cold ethanol (alcohol can be used, and the temperature of 0 ° C to 5 ° C is the result of the experiment with data) After washing twice, it is washed with nucleic acid. Such washing can remove organic impurities such as plant sterols (? -Sitosterol (C ₂₉ ) and campesterol (C ₂₈ )). Through the above steps, a lutein crystal having a purity of about 70% is produced.

In the next step, a 1: 1 mixture of dichloromethane and nucleic acid and the lute produced in the above step are mixed with each other, cooled to 20 to 10 DEG C for 2 to 3 hours, and then cooled in a vacuum of 45 to 55 DEG C to 2 to 3 Lt; RTI ID = 0.0 > lutein. ≪ / RTI > (Step 5)

This process is followed by the fifth step of finally purifying the lutein, which is carried out by recrystallization from a binary solvent system, preferably a 1: 1 mixture of dichloromethane and nucleic acid.

Lutein is dissolved in the above dichloromethane, nucleic acid is added until the solution becomes turbid, and the mixture is allowed to stand at 20 ° C to 10 ° C to start recrystallization. It is completed by cooling for 2 to 3 hours. If the temperature is below -10 ° C, the optimum Lutein concentration is not reached. If the cooling time is less than 2 hours, the cooling effect is lowered. If the cooling time is more than 3 hours, the cooling is inhibited because of the excessive cooling.

The lutein thus obtained can be dried for 2 to 3 days under a vacuum of 45 ° C to 55 ° C to produce pure lutein having a purity of 97%.

The mixture prepared in the step of preparing the mixture containing lutein produced by the above-described method is pulverized. (Powdering step)

In the pulverizing step, the mixture is preferably pulverized to a particle size of 0.2 mm to 2 mm. This is because, when the particle size is the above, the effect of the mixture is relatively uniformly distributed.

The mixture after the pulverization step is boiled for a certain time at a specific temperature. (Steaming stage)

Preferably, the nutrient that has undergone the pulverization step is cooked at 90-100 ° C for 4 minutes to 6 minutes. If the cooking time is less than 4 minutes, the effect is insignificant. If the cooking time exceeds 6 minutes, the cooking time is too much, and the nutrient is destroyed.

And, it is preferable that the mixture is exposed to steam at 60 ° C to 80 ° C for 3 to 5 minutes immediately before proceeding to the steaming step so that the mixture is made ripe by steam.

At least 60 ° C and at least 3 minutes are effective. If the temperature exceeds 80 ° C or steam is irradiated for more than 5 minutes, it may adversely affect the composition of the mixture.

And the resulting mixture is dried at a specific temperature for a certain period of time. (Drying step)

In the drying step, it is preferable that the nutrient after the mashing step is dried at 80 to 90 ° C for 3 to 4 hours to have a moisture content of 15 to 25% and sterilized.

Here, drying to have a moisture content of 15 to 25% is intended to control the moisture content of the molded mixture according to different seasons. Furthermore, it is intended to suppress the occurrence of bacteria such as fungi when nutrients are distributed on the market.

In addition, in the above case, sterilization treatment may be performed in the drying step to remove bacteria that may be contained in the nutrient.

The mixture thus dried is filled with a capsule. (Filling step)

Thus, a capsule-type ophthalmic disease management supplementary nutrient is produced in the above-described manner. Here, the amount of the mixture contained in each capsule in the filling step is most preferably 180 mg to 220 mg per capsule.

In addition, a plurality of the filled capsules are collected and accommodated in a certain container such as a plastic bottle or the like. (Step of accommodating in a container)

[ Example ]

Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.

15 parts by weight of lutein, 5 parts by weight of zeaxanthin, 2 parts by weight of astaxanthin, 5 parts by weight of DHA, 5 parts by weight of EPA, 2 parts by weight of zinc oxide, 2 parts by weight of magnesium oxide and 3 parts by weight of inulin 3 8 parts by weight of niacin (vitamin B3), 8 parts by weight of pyridoxine (vitamin B6), 15 parts by weight of vitamin E, 15 parts by weight of vitamin C and 15 parts by weight of an excipient. The particles of the stirred mixture were pulverized to a size of about 1 mm.

The powdered mixture was vigorously stirred at 100 ° C for 5 minutes, and the resulting mixture was dried at 85 ° C for 3 to 4 hours, sterilized and filled with capsules to prepare an eye disease supplements for companion animals.

[ Experimental Example ]

1. Toxicity test of the above nutrients

In order to confirm the cytotoxicity of the nutritional agent prepared in the above example, Raw 264.7 cells and HepG2 cells were treated with a supplementary nutrient for eye diseases for companion animals at different concentrations to observe the degree of apoptosis. As a result, It was confirmed that even if the supplementary nutrient was treated, there was almost no cell death.

2. Measurement of ophthalmic inflammation of companion animals

The amount of NO, COX-2 and cytokine expressed in the companion animal fed the nutrient was measured to examine the anti-inflammatory effect of the nutrient when the nutrient prepared in the above example was ingested into the companion animal. , NO, COX-2, and cytokine were decreased.

3. Measurement of inhibitory effect of companion animal eye disease

It was confirmed that the animal experimental group ingested with the nutritional preparation prepared in the above example was inhibited the growth of dry eye conjunctivitis, ulcer, corneal ulcer, germs causing ulceration or granuloma causing inflammatory diseases.

While the present invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the scope of the present invention.

Claims (7)

For companion animal eye disease management supplementary nutrition,
Wherein the auxiliary nutrient comprises 12 to 18 parts by weight of lutein, 4 to 6 parts by weight of giazanthin, 1.5 to 2.5 parts by weight of astaxanthin, 4 to 6 parts by weight of DHA, 4 to 6 parts by weight of EPA, 2 to 4 parts by weight of inulin, 1.5 to 2.5 parts by weight of zinc, 1.5 to 2.5 parts by weight of magnesium oxide, 6 to 10 parts by weight of niacin, 6 to 10 parts by weight of pyridoxine, 12 to 18 parts by weight of vitamin E, 12 to 18 parts by weight of vitamin C, Parts were mixed and pulverized,
Drying at 90 to 100 ° C for 4 to 6 minutes and then drying to a moisture content of 15 to 25%.
A method for manufacturing a companion animal ophthalmic disease management supplementary nutrient,
The method for producing the auxiliary nutrient
17.5 to 26.5 parts by weight of an eye nutritive material consisting of lutein, giazanthin and astaxanthin, 8-12 parts by weight of omega-3 fatty acid consisting of DHA and EPA, 2-4 parts by weight of inulin, 3-5 parts by weight of oxides of zinc oxide, 5 to 10 parts by weight of vitamin C, 5 to 30 parts by weight of vitamin C, 30 to 50 parts by weight of vitamin C, and 10 to 20 parts by weight of excipient.
A powdering step of powdering the mixture;
Mixing the mixture after the pulverization step at 90 to 100 DEG C for 4 to 6 minutes;
A drying step of drying the mixture after the steaming step at 80 to 90 DEG C for 3 to 4 hours and
And filling the mixture obtained through the drying step with a capsule.
delete delete delete delete 3. The method of claim 2,
The method for producing lutein comprises the steps of: mixing 26 to 36 parts by weight of marigold powder, 40 to 50 parts by weight of ethyl acetate and 14 to 22 parts by weight of ethanol at 10 ° C to 25 ° C to prepare a mixture;
A second step of separating the marigold extract and the supernatant by adding 10 to 13 parts by weight of an aqueous sodium chloride solution based on 100 parts by weight of the mixed liquid of the first step;
A third step of discarding the supernatant separated in the second step and then washing the marigold extract with distilled water;
A fourth step of washing the marigold extract in the third step with ethanol and hexane to remove organic impurities to produce lutein;
The mixture of 1: 1 mixture of dichloromethane and nucleic acid and the lutein are mixed with each other, cooled to 20 to 10 DEG C for 2 to 3 hours, and dried in a vacuum of 45 to 55 DEG C for 2 to 3 days to produce pure lutein And a fifth step of administering the ophthalmic pharmaceutical composition.

Images